Publication | Closed Access

Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non–Small-cell Lung Cancer

Non–small-cell Lung CancerNivolumab TherapyMedicineImmunologyCell DeathImmune Checkpoint InhibitorCancer TreatmentOncologyCell BiologyLung CancerNovel Biomarker